New nemolizumab data from Galderma in prurigo nodularis and atopic dermatitis patients

Swiss independent dermatology specialist Galderma today announced the presentation of new Phase II data supporting the efficacy of its investigational monoclonal antibody, nemolizumab, at the virtual 30th EADV congress now taking place.

Results from two key trials of nemolizumab given every four weeks, demonstrate rapid onset of action and significant reduction in symptoms for patients with prurigo nodularis (PN) and atopic dermatitis (AD), and new real-world evidence highlight the PN disease burden.

"We are delighted to share new analyses and clinical trial data which reinforce nemolizumab’s therapeutic potential and comprehensive benefits across prurigo nodularis and atopic dermatitis. The scientific evidence for the critical role that the IL-31 pathway plays in the inflammatory process is growing and we are committed to continuing our work diligently to bring nemolizumab to patients living with these debilitating skin conditions,” said Dr Baldo Scassellati Sforzolini, global head of R&D, Galderma